Immunic appoints Sanjay S. Patel as CFO

Immunic, Inc., a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Sanjay S. Patel, CFA, as Chief Financial Officer, effective July 15, 2019. Mr. Patel replaces Tamara A. Seymour, who has served as the company’s Interim Chief Financial Officer since April 26, 2019.

Read more
Waste carbon streams as resources for Lanzatech's process. © Lanzatech

Novo Holdings puts $72m in Lanzatech

Novo Holdings A/S (Novo Holdings) invests $72m in LanzaTech to support development of the company’s sustainable fuels and chemicals platform
Read more
With the "BigStitcher" software you can reconstruct a sample and then rotate and turn it virtually, get an overview of the big picture or zoom into individual structures. This works both as a user, as illustrated here, and as an algorithm that analyzes the data and cannot load the entire image into RAM. Neurons expressing a specific gene are marked in green. Such data now make it possible for the first time to systematically characterize differences at the single-cell level between normal and genetically modified mice and to draw conclusions about potential behavioral changes that may result. © Preibisch Lab / Treier Lab, MDC

Google maps for tumours and organs

German researchers have developed a software that allows to manage and correct the huge amount of data generated by 3D reconstruction of tumours or organs using light sheet microscopy.
Read more
Vaccinia virus. © wikipedia/commons PHIL

Transgene’s licenced oncolytic virus fails in Phase III

SillaJen, the licensor for French immunoncology specialist Transgene SA, has stopped enrolment into the Phase III Phocus trial after an Independent Data Review Comittee predicted the study endpoint won’t be met.

Read more

Pieris Pharmaceuticals appoints Dr. Maya Said

Pieris Pharmaceuticals, Inc. today announced that Maya R. Said, Sc.D., has joined the Company’s Board of Directors.

Read more
Wellington Partner's Managing Partner Rainer Strohmenger. © UroMems

Wellington Partners launch €210m Life Sciences fund

Wellington Partners has closed its largest Life Sciences Fund ever. The VC specialist outperformed its intial target of raising €120m to €150m and closed at €210m.

Read more
© pixabay/julientromeur

Alizé Pharma 3 bags largest EU financing so far

Venture Captital specialist LSP led a €67m Series A financing in peptide developer Alizé Pharma 3.

Read more
Microscopic images of either wild type (left) or mutant (right) HeLa cells treated with TNF-alpha. © P.E. Morton et al., Science Signaling (2019)

Better TNF? receptor blockers on the horizon

Two research teams have unraveled the complex dynamics of TNF? receptor signaling and have identified compounds that may be safer than current treatments.

Read more
Dr. Michael Merz

We need predictive safety biomarkers

Every year, drug developers lose billions of euros because of late-stage clinical or postmarking safety problems with drugs. A recently kicked-off IMI consortium now wants to qualify a set of safety biomarkers that allow for the prediction of drug-induced injury of kidney, liver, vasculature, CNS, and pancreas. European Biotechnology spoke with Dr Michael Merz, the coordinator of the TransBioLine Project, and consortium member Prof Dr Stefan Wnendt about the plans and impact of the project.

Read more
Agrosavfe's agrocapsules are made by coupling stable camelid agrobodies to microcapsules containing active substances to protect seeds, crops and produce from weeds, pests and diseases. © AgroSavfe NV

AgroSavfe raises €35m in Series C financing

Plant protection specialist AgroSavfe will use the funds of a €35m Series C financing to push the development, registration and commercial scale production of its biofungicides and bio-insecticide.

Read more